Inhibitors targeting PD-L1 palmitoylation were proved to be effective to overcome PD-L1-mediated immune evasion.519 Anti-PD-1/PD-L1 agents and combination therapies with hundreds of chemotherapies, radiotherapy, and anti-angiogenic agents have been tested in active clinical trials and serve as promising attempt in the cancer immunotherapy field.520 Targeting the novel interchange between various PTMs of PD-L1 protein offer novel opportunities to combat immune surveillance and develop more effective drugs and treatments from a new perspective. The gene discussed is PDCD1; the disease is cancer.